Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report series
IntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolerability and support within-class switching for pa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1527102/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | IntroductionAnti-CD20 monoclonal antibody (mAb) therapies used to treat multiple sclerosis (MS) differ in their molecular structures, epitope recognition, and mechanisms of CD20-positive (CD20+) cell lysis, which may impact clinical efficacy and tolerability and support within-class switching for patients with suboptimal response to a prior anti-CD20 mAb.Patients and methodsThis is a retrospective case series of 7 individuals with MS treated in private practice or at an MS clinic who switched to ublituximab from a different anti-CD20 mAb therapy due to efficacy or tolerability concerns.Case descriptionsDetails of each case, including clinical and/or radiological outcomes on initial anti-CD20 mAb therapy, reasons for switching, and outcomes after starting ublituximab therapy are provided.DiscussionThese cases highlight suboptimal B-cell depletion, inadequate MS disease control, and/or tolerability concerns in people with MS who had clinical improvements or stabilization of disease following a switch from ocrelizumab or rituximab to ublituximab.ConclusionWithin-class switching from a prior anti-CD20 mAb therapy to ublituximab is feasible and may improve outcomes in some people with MS. |
|---|---|
| ISSN: | 1664-3224 |